Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Prostate Cancer

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 34 articles: HTML format

Single Articles

January 2024
1. SHORE ND, Tarazi J, Freedland SJ
   Enzalutamide in Biochemically Recurrent Prostate Cancer. Reply.
   N Engl J Med. 2024;390:90-91.
   PubMed    
   
   
   
2. POLLAK M
   Enzalutamide in Biochemically Recurrent Prostate Cancer.
   N Engl J Med. 2024;390:90.
   PubMed    
   
   
   October 2023
3. APARICIO A
   Biochemical Recurrence in Prostate Cancer - Tilting the Scale.
   N Engl J Med. 2023;389:1522-1523.
   PubMed    
   
   
   
4. FREEDLAND SJ, de Almeida Luz M, De Giorgi U, Gleave M, et al
   Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
   N Engl J Med. 2023;389:1453-1465.
   PubMed     Abstract available
   
   
   
5. NADAMUNI M, D'Amico AV, Donovan JL, Hamdy FC, et al
   Decision Making in Prostate Cancer.
   N Engl J Med. 2023;389:1335-1338.
   PubMed    
   
   
   July 2023
6. PINSKY PF, Parnes H
   Screening for Prostate Cancer. Reply.
   N Engl J Med. 2023;389:94.
   PubMed    
   
   
   
7. PRESTI J JR, Alexeeff S, Avins AL
   Screening for Prostate Cancer.
   N Engl J Med. 2023;389:93-94.
   PubMed    
   
   
   
8. INAMURA K
   Screening for Prostate Cancer.
   N Engl J Med. 2023;389:93.
   PubMed    
   
   
   
9. HOOVER J, Butterfass C, Ponder A
   Screening for Prostate Cancer.
   N Engl J Med. 2023;389:92-93.
   PubMed    
   
   
   
10. HAMDY FC, Donovan JL
    Fifteen-Year Outcomes of the ProtecT Trial for Localized Prostate Cancer. Reply.
    N Engl J Med. 2023;389:92.
    PubMed    
    
    
    
11. DAVIS MJ, Stephens A, Abdollah F
    Fifteen-Year Outcomes of the ProtecT Trial for Localized Prostate Cancer.
    N Engl J Med. 2023;389:90-92.
    PubMed    
    
    
    June 2023
12. 
    Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    N Engl J Med. 2023;388:2208.
    PubMed    
    
    
    April 2023
13. 
    Waiting on Prostate Cancer.
    N Engl J Med. 2023;388:e54.
    PubMed    
    
    
    
14. PINSKY PF, Parnes H
    Screening for Prostate Cancer.
    N Engl J Med. 2023;388:1405-1414.
    PubMed    
    
    
    March 2023
15. SARTOR O
    Localized Prostate Cancer - Then and Now.
    N Engl J Med. 2023 Mar 11. doi: 10.1056/NEJMe2300807.
    PubMed    
    
    
    
16. HAMDY FC, Donovan JL, Lane JA, Metcalfe C, et al
    Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    N Engl J Med. 2023 Mar 11. doi: 10.1056/NEJMoa2214122.
    PubMed     Abstract available
    
    
    February 2023
17. FIZAZI K, Piulats JM, Reaume MN, Ostler P, et al
    Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
    N Engl J Med. 2023 Feb 16. doi: 10.1056/NEJMoa2214676.
    PubMed     Abstract available
    
    
    
18. GAGLIANO-JUCA T, Hirsch MS, McGregor BA, Basaria S, et al
    Failure of Androgen-Deprivation Therapy Due to Ectopic hCG Secretion.
    N Engl J Med. 2023;388:660-662.
    PubMed    
    
    
    December 2022
19. GULATI R
    Reducing Prostate Cancer Overdiagnosis.
    N Engl J Med. 2022;387:2187-2188.
    PubMed    
    
    
    
20. HUGOSSON J, Mansson M, Wallstrom J, Axcrona U, et al
    Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only.
    N Engl J Med. 2022;387:2126-2137.
    PubMed     Abstract available
    
    
    September 2022
21. 
    Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
    N Engl J Med. 2022;387:860.
    PubMed    
    
    
    June 2022
22. SMITH MR
    Darolutamide in Metastatic Prostate Cancer. Reply.
    N Engl J Med. 2022;386:2345.
    PubMed    
    
    
    
23. BOWLING GC, Dimitrakoff JD
    Darolutamide in Metastatic Prostate Cancer.
    N Engl J Med. 2022;386:2344.
    PubMed    
    
    
    
24. TURCO F, Tucci M, Buttigliero C
    Darolutamide in Metastatic Prostate Cancer.
    N Engl J Med. 2022;386:2344.
    PubMed    
    
    
    February 2022
25. SMITH MR, Hussain M, Saad F, Fizazi K, et al
    Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
    N Engl J Med. 2022 Feb 17. doi: 10.1056/NEJMoa2119115.
    PubMed     Abstract available
    
    
    December 2021
26. SARTOR O, Morris MJ, Kraus BJ
    Lutetium-177-PSMA-617 for Prostate Cancer. Reply.
    N Engl J Med. 2021;385:2495-2496.
    PubMed    
    
    
    
27. DALLA VOLTA A, Grisanti S, Berruti A
    Lutetium-177-PSMA-617 for Prostate Cancer.
    N Engl J Med. 2021;385:2495.
    PubMed    
    
    
    
28. KASHIHARA T, Kashihara K
    Lutetium-177-PSMA-617 for Prostate Cancer.
    N Engl J Med. 2021;385:2494-2495.
    PubMed    
    
    
    
29. HINDIE E
    Lutetium-177-PSMA-617 for Prostate Cancer.
    N Engl J Med. 2021;385:2494.
    PubMed    
    
    
    November 2021
30. EKLUND M, Discacciati A, Nordstrom T
    MRI-Targeted Biopsy in Prostate Cancer Screening. Reply.
    N Engl J Med. 2021;385:2110-2111.
    PubMed    
    
    
    
31. YOSHIDA S, Fujii Y
    MRI-Targeted Biopsy in Prostate Cancer Screening.
    N Engl J Med. 2021;385:2110.
    PubMed    
    
    
    
32. AL HUSSEIN AL AWAMLH B, Spratt DE, Shoag JE
    MRI-Targeted Biopsy in Prostate Cancer Screening.
    N Engl J Med. 2021;385:2109-2110.
    PubMed    
    
    
    July 2021
33. EKLUND M, Jaderling F, Discacciati A, Bergman M, et al
    MRI-Targeted or Standard Biopsy in Prostate Cancer Screening.
    N Engl J Med. 2021 Jul 9. doi: 10.1056/NEJMoa2100852.
    PubMed     Abstract available
    
    
    June 2021
34. SARTOR O, de Bono J, Chi KN, Fizazi K, et al
    Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
    N Engl J Med. 2021 Jun 23. doi: 10.1056/NEJMoa2107322.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.